AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
AstraZeneca Plc got rid of its 7.7% stake in Moderna, and it was sold for more than $1 billion. The sale happened following the surge of the British–Swedish multinational pharmaceutical and biopharmaceutical company’s shares due to its COVID-19 vaccine breakthrough.
The stake selling move by the pharma firm
Then again, Reuters reported that it is not clear as to when AstraZeneca sold its Moderna stake. When contacted to clarify and provide more details about the matter, the outlet stated that both AstraZeneca and Moderna were not able to respond to the requests for comments immediately.
But despite the sale, it was said that AstraZeneca will still retain its team up with Moderna Inc. for the research and production of drugs for treating other diseases. The British–Swedish pharmaceutical company may also sell its AstraZeneca/Oxford University coronavirus vaccine on a commercial scale in the future if COVID-19 becomes endemic.
At any rate, the vaccine that Moderna made for COVID-19 has been approved by the Food and Drug Administration (FDA) for emergency use in the U.S. With its vaccine alone, the American pharmaceutical and biotechnology company says it is expecting $18.4 billion from the sale of its coronavirus vaccine this year.
How AstraZeneca will use the cash from the sale
The Times reported that AstraZeneca was Moderna’s second-biggest investor in 2020, but now it has sold its 7.7% stakes. The gains from the sale of Moderna holding is equivalent to $1.2 billion, and this will be added to Astra’s funds intended for developing its own drug line.
Part of the cash will also be used to complete AstraZeneca’s purchase of the American pharmaceutical that makes drugs for the treatment of rare diseases and disorders, Alexion. This was purchased by Astra for $39 billion, which makes it the company’s biggest acquisition.
AstraZeneca’s purchase of Alexion was announced in December 2020. It was announced that the rare disease unit would be based in Boston once the deal is completed. Finally, the procurement of the pharma firm will strengthen AstraZeneca’s income and will further help Alexion’s presence on the global stage to become more prominent.
